In order to ensure that you continue to receive information that is of interest from PharmaVentures help us by subscribing. Thank you for your co-operation. Pharmaceutical Deal Structures - The Essential Manual for Deal Makers This indispensable report allows even the most experienced deal makers to translate theoretical discussions into reality. It is a comprehensive source of information relating to all deal structures and is the ultimate reference guide for anyone involved in business development or licensing. Read more... Market News and Trends In June 2005, PharmaDeals® Agreements recorded 22 deals relating to drug delivery. Of the deals announced in June, three involved business acquisitions: Edot.com announced on the 3rd June that it was to acquire 100% of the common stock of NanoViricides; Emergent BioSolutions announced on the 27th June that it is to acquire UK-based Microscience; and ML Laboratories announced on the 16th June that it has agreed terms for the proposed acquisition of Quadrant Technologies. Read more... Featured Article Recent Developments in Intranasal Drug Delivery Technology are Creating New Vistas for Peptide and Protein Therapeutics The recent advent of highly efficient transmucosal delivery agents offers many practical opportunities for drug companies to start embracing the broad use of proteins as human therapeutics. They are also creating new commercial and clinical opportunities for both major pharmaceutical and smaller biopharmaceutical companies. Dr Edward Maggio, Aegis Therapeutics, discusses the improvements in intranasal therapy with a particular focus on proteins and peptides. Read more... Company Profiles Baxter, Bespak, Cardinal Health, Pro-Med Drug Delivery Opportunities View all our Drug Delivery Opportunities or alternatively request a password to submit your opportunity online. Featured Opportunity Respiratory Combination Therapy for Asthma and Rhinitis Administrative route - Nasal, Inhalation, Oral Indication - Co-existing asthma and allergic rhinitis Licence code LO-0605-06 Make sure your company is profiled in this unique deal making publication! "The key benefit of this report is that it is a one stop shop for current drug delivery information. I like the concise overview of the companies presented and I am unaware of any other publication offering the same service." Mark Rowlands, Business Development Manager, Innovata Biomed Find out about profiling your company in the Autumn/Winter 2005 Drug Delivery Report. Senior decision makers from the Pharma and Biotech sectors actively assess the drug delivery opportunities profiled in the DDR. If you are looking to complete a deal in 2005 the DDR is an important place for you to promote your company.
Drug Delivery E-News is produced by PharmaVentures Intelligence, part of PharmaVentures - a leading results driven organisation assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making. Comprising two specialist areas - PharmaVentures Consulting and PharmaVentures Intelligence, we work with clients to drive greater value from their deals. If you do not wish to receive DDR E-News in future, please e-mail ddcr@pharmamail.biz with the words UNSUBSCRIBE as the subject. If you do not wish to receive other e-mail communications from PharmaVentures or selected third parties, please e-mail ddcr@pharmamail.biz with REMOVE as the subject. For more details contact Mel Hemamda, Product Manager, PharmaVentures Ltd, Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK. Tel: +44 (0) 1865 784 177 Fax: +44 (0) 1865 784 178 E-mail enquiries@ddcr.com www.ddcr.com